871476-72-1Relevant academic research and scientific papers
Non-nucleoside reverse transcriptase inhibitors
-
Page/Page column 22, (2008/06/13)
The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, X1 and X2 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.
Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases
Gagnon, Alexandre,Amad, Ma'an H.,Bonneau, Pierre R.,Coulombe, Rene,DeRoy, Patrick L.,Doyon, Louise,Duan, Jianmin,Garneau, Michel,Guse, Ingrid,Jakalian, Araz,Jolicoeur, Eric,Landry, Serge,Malenfant, Eric,Simoneau, Bruno,Yoakim, Christiane
, p. 4437 - 4441 (2008/02/11)
A series of aryl thiotetrazolylacetanilides were synthesized and found to be potent inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases. The incorporation of an alkynyl fragment on the aniline provided inhibitors with ex
NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
-
Page/Page column 89, (2008/06/13)
The invention relates to compounds of formula (I) wherein Ar, X, R1, R2, R3 and R4 are as defined herein and, pharmaceutical compositions thereof useful, either alone or in combination with other therapeutic agents as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV for the treatment or prophylaxis of HIV infection
